Dongwha Pharm.Co.,Ltd (000020.KS)
KRW 6360.0
(-1.7%)
KRW 6360.0
(-1.7%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 157.65 Billion KRW | 91.18% |
| 2022 | 82.46 Billion KRW | -5.94% |
| 2021 | 87.67 Billion KRW | -3.79% |
| 2020 | 91.12 Billion KRW | 21.25% |
| 2019 | 75.15 Billion KRW | 2.67% |
| 2018 | 73.19 Billion KRW | 4.15% |
| 2017 | 70.28 Billion KRW | -1.95% |
| 2016 | 71.67 Billion KRW | -17.68% |
| 2015 | 87.06 Billion KRW | 4.47% |
| 2014 | 83.34 Billion KRW | -6.28% |
| 2013 | 88.93 Billion KRW | -8.59% |
| 2012 | 97.29 Billion KRW | -11.4% |
| 2011 | 109.8 Billion KRW | -0.26% |
| 2010 | 110.09 Billion KRW | 9.97% |
| 2009 | 100.11 Billion KRW | -5.65% |
| 2008 | 106.1 Billion KRW | 157.04% |
| 2007 | 41.28 Billion KRW | 11.72% |
| 2006 | 36.95 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 149.38 Billion KRW | -2.22% |
| 2024 Q1 | 152.78 Billion KRW | -3.09% |
| 2023 Q3 | 89.41 Billion KRW | 2.58% |
| 2023 Q4 | 157.65 Billion KRW | 76.32% |
| 2023 Q1 | 90.03 Billion KRW | 9.18% |
| 2023 Q2 | 87.16 Billion KRW | -3.18% |
| 2023 FY | 157.65 Billion KRW | 91.18% |
| 2022 Q3 | 96.45 Billion KRW | -2.24% |
| 2022 Q4 | 82.46 Billion KRW | -14.51% |
| 2022 FY | 82.46 Billion KRW | -5.94% |
| 2022 Q2 | 98.66 Billion KRW | -1.08% |
| 2022 Q1 | 99.73 Billion KRW | 13.76% |
| 2021 Q4 | 87.67 Billion KRW | -7.45% |
| 2021 Q2 | 95.99 Billion KRW | -0.07% |
| 2021 FY | 87.67 Billion KRW | -3.79% |
| 2021 Q3 | 94.73 Billion KRW | -1.32% |
| 2021 Q1 | 96.06 Billion KRW | 5.42% |
| 2020 Q3 | 92.29 Billion KRW | 19.7% |
| 2020 FY | 91.12 Billion KRW | 21.25% |
| 2020 Q1 | 76.69 Billion KRW | 2.06% |
| 2020 Q2 | 77.1 Billion KRW | 0.53% |
| 2020 Q4 | 91.12 Billion KRW | -1.26% |
| 2019 Q4 | 75.15 Billion KRW | -6.82% |
| 2019 FY | 75.15 Billion KRW | 2.67% |
| 2019 Q3 | 80.65 Billion KRW | -1.5% |
| 2019 Q2 | 81.88 Billion KRW | 8.14% |
| 2019 Q1 | 75.72 Billion KRW | 3.45% |
| 2018 Q3 | 72.05 Billion KRW | -5.42% |
| 2018 Q2 | 76.17 Billion KRW | -7.11% |
| 2018 Q1 | 82.01 Billion KRW | 16.69% |
| 2018 FY | 73.19 Billion KRW | 4.15% |
| 2018 Q4 | 73.19 Billion KRW | 1.59% |
| 2017 Q4 | 70.28 Billion KRW | -14.16% |
| 2017 Q3 | 81.87 Billion KRW | 8.06% |
| 2017 Q1 | 69.26 Billion KRW | -3.37% |
| 2017 FY | 70.28 Billion KRW | -1.95% |
| 2017 Q2 | 75.76 Billion KRW | 9.38% |
| 2016 FY | 71.67 Billion KRW | -17.68% |
| 2016 Q2 | 96.64 Billion KRW | 6.93% |
| 2016 Q3 | 93.23 Billion KRW | -3.53% |
| 2016 Q4 | 71.67 Billion KRW | -23.12% |
| 2016 Q1 | 90.37 Billion KRW | 3.8% |
| 2015 Q4 | 87.06 Billion KRW | -3.23% |
| 2015 Q3 | 89.97 Billion KRW | 0.95% |
| 2015 Q2 | 89.12 Billion KRW | 0.5% |
| 2015 Q1 | 88.68 Billion KRW | 6.4% |
| 2015 FY | 87.06 Billion KRW | 4.47% |
| 2014 Q1 | 89.5 Billion KRW | 0.64% |
| 2014 FY | 83.34 Billion KRW | -6.28% |
| 2014 Q4 | 83.34 Billion KRW | -8.5% |
| 2014 Q3 | 91.09 Billion KRW | 0.06% |
| 2014 Q2 | 91.03 Billion KRW | 1.71% |
| 2013 Q4 | 88.93 Billion KRW | -4.56% |
| 2013 FY | 88.93 Billion KRW | -8.59% |
| 2013 Q1 | 110.5 Billion KRW | 13.59% |
| 2013 Q2 | 98.89 Billion KRW | -10.51% |
| 2013 Q3 | 93.18 Billion KRW | -5.77% |
| 2012 Q2 | 112.53 Billion KRW | -0.92% |
| 2012 Q1 | 113.57 Billion KRW | 3.44% |
| 2012 Q4 | 97.29 Billion KRW | -1.82% |
| 2012 FY | 97.29 Billion KRW | -11.4% |
| 2012 Q3 | 99.09 Billion KRW | -11.94% |
| 2011 Q4 | 109.8 Billion KRW | 1.96% |
| 2011 Q1 | 114.98 Billion KRW | 4.45% |
| 2011 FY | 109.8 Billion KRW | -0.26% |
| 2011 Q3 | 107.69 Billion KRW | -8.26% |
| 2011 Q2 | 117.4 Billion KRW | 2.1% |
| 2010 Q3 | 112.41 Billion KRW | 1.12% |
| 2010 FY | 110.09 Billion KRW | 9.97% |
| 2010 Q4 | 110.09 Billion KRW | -2.07% |
| 2010 Q1 | 108.13 Billion KRW | 0.0% |
| 2010 Q2 | 111.17 Billion KRW | 2.81% |
| 2009 Q2 | 109.23 Billion KRW | 2.94% |
| 2009 Q1 | 106.1 Billion KRW | -13.89% |
| 2009 FY | 100.11 Billion KRW | -5.65% |
| 2009 Q3 | 98.39 Billion KRW | -9.92% |
| 2008 Q4 | 123.23 Billion KRW | 75.13% |
| 2008 Q1 | 41.28 Billion KRW | -20.09% |
| 2008 Q2 | 48.12 Billion KRW | 16.58% |
| 2008 FY | 106.1 Billion KRW | 157.04% |
| 2008 Q3 | 70.36 Billion KRW | 46.21% |
| 2007 FY | 41.28 Billion KRW | 11.72% |
| 2007 Q2 | 39.89 Billion KRW | 0.0% |
| 2007 Q3 | 40.38 Billion KRW | 1.23% |
| 2007 Q4 | 51.66 Billion KRW | 27.92% |
| 2006 FY | 36.95 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -102.493% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 83.044% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 77.704% |
| HANDOK Inc. | 449.7 Billion KRW | 64.942% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -84.027% |
| Yuhan Corporation | 712.33 Billion KRW | 77.868% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 75.051% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -891.897% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 81.492% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -194.528% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 23.421% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -109.731% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -6.673% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -123.94% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -102.493% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -332.692% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 37.226% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 28.567% |
| JW Holdings Corporation | 827.51 Billion KRW | 80.948% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 63.923% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 73.132% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 58.467% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -98.807% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -125.328% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 35.081% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 52.268% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -102.493% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 67.826% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 81.626% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 58.467% |
| Yuhan Corporation | 712.33 Billion KRW | 77.868% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 67.004% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -15.104% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 69.486% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 58.467% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -2.019% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -75.242% |
| CKD Bio Corp. | 170.76 Billion KRW | 7.674% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 35.316% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -266.481% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -98.807% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 75.075% |
| Boryung Corporation | 373.1 Billion KRW | 57.745% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 24.275% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 23.421% |
| JW Lifescience Corporation | 96.44 Billion KRW | -63.471% |